GSK suffers pipeline setbacks
November 1, 2006Research and Development
A series of problems with GlaxoSmithKline's late stage product pipeline has taken the shine off its third quarter figures.The company …
Pharma’s evolving relationship with NICE
November 1, 2006Research and Development, Sales and Marketing NHS, NICE, approval process, fast track, healthcare
Back when New Labour was only halfway through its first term of office and when the Millennium Bug was feared …
Has pharma got the feelgood factor?
October 30, 2006Business Services HR, recruitment
People are expecting more from their jobs than they ever have before. The concept of a job for life – …
Modified mice could speed safe drug discoveries
October 27, 2006Research and Development
CXR Biosciences, based in Scotland, and Artemis Pharmaceuticals in Germany, have been granted licences to sell their genetically modified mice, …
Protest against NHS cuts gathers momentum
October 26, 2006Protests against planned cuts to NHS services are taking place around the UK, with anger rising in a number of …
Most PCTs not funding Pfizer’s Macugen
October 26, 2006Patients with wet, age-related macular degeneration are being denied access to the first of a new class of treatment for …
Bristol-Myers Squibb suffers at hands of generic Plavix
October 26, 2006Sales and Marketing
Figures show that the launch of a generic competitor to Plavix in the US dealt a serious blow to Bristol-Myers …
Takeda launches Actos combination in UK
October 26, 2006Sales and Marketing
Takeda has expanded its type II diabetes portfolio in the UK with the launch of Competact, a combination of the …
Cerovive failure another blow for AstraZeneca
October 26, 2006Research and Development, Sales and Marketing AstraZeneca, Cerovive, neuroscience
A drug which had held out the promise of reducing the disabling effects of stroke on patients will be abandoned …
Lilly underlines its position as major biotech company
October 25, 2006Research and Development
Eli Lilly has opened the first phase of a $560 million expansion to its US biotech research complex.The news comes …
Freedom to Prescribe v The Formulary
October 24, 2006GP, NHS, doctors, healthcare
The modern concept of a formulary embraces three basic principles: first, it is a limited list of treatments chosen from …
EU recommends first ever therapy for Hunter syndrome
October 24, 2006Sales and Marketing
Shire has received full EU recommendation for the use of Elaprase for the long-term treatment of patients with Hunter syndrome.Marketing …
Industry calls for global healthcare systems to be benchmarked
October 13, 2006Sales and Marketing
Fred Hassan, chief executive of Schering-Plough and new head of an international pharma industry organisation, has called for greater transparency …
New schizophrenia treatment promises no weight gain side-effects
October 13, 2006Sales and Marketing
Solvay and Wyeth have filed a new treatment for schizophrenia with the US regulators, which promises to be free of …
Watchdog urges NHS to ‘raise its game’
October 12, 2006An NHS watchdog has told managers the health service must raise its game following a national review of performance revealed …
From surgery to pharmacy
October 12, 2006Sales and Marketing P, POM, marketing, reclassification, sales
Pfizer buys British vaccine company PowderMed
October 12, 2006Research and Development Pfizer, Powdermed, vaccines
Pfizer will gain entry into the fast-growing vaccines market by buying PowderMed, the British company developing next generation products in …
Alzheimer’s drug ruling ”a terrible decision”
October 11, 2006Sales and Marketing
Campaigners are stunned at NICE's final decision not to allow Alzheimer's drugs to be prescribed on the NHS in the …
Takeda retains The Remedy for European events
October 6, 2006Medical Communications
Takeda Europe has re-appointed marketing firm The Remedy to run its pan-European and international meetings for 2007.The Remedy, which is …
Amgen to acquire Avidia
October 5, 2006Research and Development, Sales and Marketing
Amgen is to pay $290 million to buy Avidia, a Californian biotech company which is developing innovative new protein-based medicines.Based …
Latest content
